Journal of Cancer Biology and Therapeutics最新文献

{"title":"BIW-8962, an Anti GM2 Ganglioside Monoclonal Antibody, in Previously Treated Advanced/Recurrent Lung Cancer: a Phase I/II Study","authors":"V. Strout, Keunchil Park, J. Lee, Sang-We Kim, Jin-Hyoung Kang, Dae-Ho Lee, B. Cho, N. Shiraishi, Joo‐Hang Kim","doi":"10.18314/gjct.v4i1.1375","DOIUrl":"https://doi.org/10.18314/gjct.v4i1.1375","url":null,"abstract":"BIW-8962 is a monoclonal antibody to GM2 ganglioside that shows pre-clinical activity towards lung cancer cell lines and in an animal model bearing small-cell lung cancer (SCLC) xenografts. In phase I, patients (N=16) with advanced, recurrent lung cancer received BIW-8962 (1-10 mg/kg) intravenously every 3 weeks. There were no dose-limiting toxicities and the maximum tolerated dose was not established. The highest dose (10 mg/kg) was administered to patients with advanced, recurrent SCLC (N=21) in phase II. The phase II study was prematurely terminated due to lack of efficacy. Objective response rate was 5% (95% CI: 0.1-24.9%) in the efficacy evaluable population (N=20). One patient showed a durable partial response and there were a few with stable disease, which was generally not durable. No pattern of consistent toxicity was observed across the phases: there were no treatment-related adverse events (AEs) grade ? 3, serious AEs, AEs leading to discontinuation of BIW-8962, or deaths. Exploratory analysis of circulating tumor cells and other potentially predictive orpharmacodynamic markers did not reveal any results consistent with an effect from BIW-8962. Given the complete lack of response in the study population, further development of BIW- 8962 has been discontinued. The reason for the lack of clinical activity with BIW-8962 is unknown. It is hoped that the negative findings of this study will contribute to other investigations of GM2 as a therapeutic target, possibly by combination therapy, and of alternative tumor markers in patients with SCLC.","PeriodicalId":140922,"journal":{"name":"Journal of Cancer Biology and Therapeutics","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123885284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Turcot Syndrome: A Synchronous Clinical Presentation of Medulloblastoma and Lower Rectal Tumor","authors":"Mehdi Borni, F. Kolsi, B. Kammoun, M. Boudawara","doi":"10.18314/gjct.v4i1.1304","DOIUrl":"https://doi.org/10.18314/gjct.v4i1.1304","url":null,"abstract":"We report the case of a 16-year-old patient who was operated for medulloblastoma with simple operative followup after radio and chemotherapy. Two years later, she was admitted, in a state of cachexia, for abdominal pain and rectorrhagia. The explorations found an infected lower rectal tumor. The patient underwent an urgent surgery. Immediate consequences were marked by the installation of a severe septic shock causing the patient’s death.","PeriodicalId":140922,"journal":{"name":"Journal of Cancer Biology and Therapeutics","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124745938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration of Beta-Emitting Anti-CD37 Radioimmunoconjugate Lutetium (177Lu) Lilotomab Satetraxetan as Weekly Multiple Injections Increases Maximum Tolerated Activity in Nude Mice with Non- Hodgkin Lymphoma Xenografts","authors":"H. Heyerdahl, A. Repetto-Llamazares, J. Dahle","doi":"10.18314/gjct.v4i1.1091","DOIUrl":"https://doi.org/10.18314/gjct.v4i1.1091","url":null,"abstract":"Lutetium (177Lu) lilotomab satetraxetan (177Lu-lilotomab) is a novel anti-CD37 radioimmunoconjugate (RIC) currently in Phase 2b clinical trial for treatment of non-Hodgkin lymphoma (NHL). The aim of the current study was to investigate tolerability and anti-tumor efficacy of multiple dosing of 177Lu-lilotomab in vivo. Nude mice with subcutaneous (s.c.) NHL (Ramos) xenografts were given 2, 3 or 4 weekly injections of 300 MBq/kg 177Lu-lilotomab or NaCl. Treatment tolerability was assessed by body weight, hematology and histopathological evaluation. A separate experiment in mice without xenografts was performed to collect long term toxicity data. Mice in this study were dosed more conservatively with the intention that all mice should survive until end of experiment and were administered 2 or 4 weekly injections of 200 MBq/kg 177Lu-lilotomab or NaCl. Total accumulated activity of 900 MBq/kg 177Lu-lilotomab given as three weekly injections was tolerated by nude mice with s.c. Ramos xenografts, which is 50 % higher than the maximum tolerated activity (MTA) of a single injection of 530-600 MBq/kg. In the long-term toxicity animals, the highest accumulated activity tested, 800 MBq/kg, was also well tolerated. Radioactivity-dependent transient reduction in white blood cell and platelet counts occurred in all treated groups, with nadir 1-3 weeks after last injection. This toxicity was radioactivity dependent and consistent with histopathological changes in hemolymphopoietic tissues. Significant tumor growth delay measured as time to reach 4 times intial tumor volume was observed in all groups given multiple injections of 300 MBq/kg 177Lu-lilotomab compared to NaCl control group (p<0.001). In conclusion, weekly injections of 177Lu-lilotomab increase the accumulated MTA from 530 to 900 MBq/kg in nude mice, allowing the total injected activity and hence the radiation dose to tumor to be increased without increasing the toxicity to normal tissues.","PeriodicalId":140922,"journal":{"name":"Journal of Cancer Biology and Therapeutics","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133206166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examination of Factors Influencing the Success Rates of an In Vitro Chemosensitivity Test for Lung Cancer Using Collagen Gel Droplet-Embedded Cultures","authors":"Takahara Y, Kawasaki Y, Kato R, S. S, Oikawa T, M. S","doi":"10.18314/gjct.v5i1.1974","DOIUrl":"https://doi.org/10.18314/gjct.v5i1.1974","url":null,"abstract":"Objective: We evaluated the success rates and factors influencing the success rates of the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test (CD-DST) for pleural effusate in lung cancer patients with carcinomatous pleurisy.Materials and methods: Thirty-two patients with lung cancer having carcinomatous pleurisy were enrolled in this study between January 2014 and May 2017. Their pleural effusions were analysed by CD-DST, and the subjects were classified into two groups: successful cases and unsuccessful cases, based on whether the test was able to successfully determine drug sensitivity. We investigated whether the properties of the pleural effusate might influence the success rate of CD-DST. We observed that the CD-DST tended to have good success rates in patients with higher pH, higher percentage of lymphocytes, higher cell counts, and lower percentage of neutrophils in their pleural effusate. The red blood cell count was higher in the effusate of unsuccessful than successful cases.Conclusion: Our results suggest that the diagnostic success rates of CD-DST for pleural effusion from patients with lung cancer might improve by appropriate sample selection.","PeriodicalId":140922,"journal":{"name":"Journal of Cancer Biology and Therapeutics","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122677989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}